Retrophin Company Profile (NASDAQ:RTRX)

About Retrophin

Retrophin logoRetrophin, Inc. is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Its product candidates include Sparsentan, RE-024, RE-034 and NGLY1.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RTRX
  • CUSIP:
Key Metrics:
  • Previous Close: $20.57
  • 50 Day Moving Average: $19.65
  • 200 Day Moving Average: $19.96
  • 52-Week Range: $37,732,000.00 - $11.60
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -187.91
  • P/E Growth: -0.78
  • Market Cap: $779.92M
  • Outstanding Shares: 37,732,000
  • Beta: 1.12
Profitability:
  • Net Margins: -32.96%
  • Return on Equity: -1.33%
  • Return on Assets: -0.79%
Debt:
  • Debt-to-Equity Ratio: 0.14%
  • Current Ratio: 3.98%
  • Quick Ratio: 3.95%
Additional Links:
Companies Related to Retrophin:

Analyst Ratings

Consensus Ratings for Retrophin (NASDAQ:RTRX) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $35.33 (70.94% upside)

Analysts' Ratings History for Retrophin (NASDAQ:RTRX)
Show:
DateFirmActionRatingPrice TargetDetails
12/14/2016BMO Capital MarketsSet Price TargetBuy$46.00View Rating Details
12/15/2016JMP SecuritiesSet Price TargetBuy$28.00View Rating Details
9/7/2016Leerink SwannBoost Price TargetOutperform$27.00 -> $32.00View Rating Details
6/4/2015Deutsche Bank AGBoost Price TargetBuy$52.00 -> $55.00View Rating Details
5/23/2015NomuraReiterated RatingBuy$31.00 -> $34.00View Rating Details
5/15/2015Avondale PartnersInitiated CoverageOutperform$39.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Retrophin (NASDAQ:RTRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017        
11/3/2016Q3$0.38($0.09)$34.84 million$33.95 millionViewN/AView Earnings Details
5/3/2016Q1($0.22)$0.14$31.00 million$29.00 millionViewN/AView Earnings Details
2/25/2016Q4($0.22)$0.07$29.40 million$30.40 millionViewListenView Earnings Details
11/3/2015Q3$0.09($0.04)$27.35 million$28.00 millionViewN/AView Earnings Details
8/4/2015Q215($0.42)$0.40$20.52 million$24.10 millionViewN/AView Earnings Details
5/11/2015Q115($0.50)($0.04)$17.40 millionViewListenView Earnings Details
3/5/2015Q414($0.36)$14.10 millionViewListenView Earnings Details
11/13/2014Q3($0.53)ViewListenView Earnings Details
8/12/2014Q214($0.52)$5.74 millionViewN/AView Earnings Details
5/14/2014Q114($0.44)($3.03)$0.80 million$0.03 millionViewListenView Earnings Details
3/27/2014($0.30)($0.76)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Retrophin (NASDAQ:RTRX)
Current Year EPS Consensus Estimate: $-1.32 EPS
Next Year EPS Consensus Estimate: $-0.11 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.26)($0.26)($0.26)
Q2 20161($0.27)($0.27)($0.27)
Q3 20161($0.24)($0.24)($0.24)
Q4 20161($0.26)($0.26)($0.26)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Retrophin (NASDAQ:RTRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Retrophin (NASDAQ:RTRX)
Insider Ownership Percentage: 2.41%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/22/2016Steve AselageCEOSell8,200$21.12$173,184.00View SEC Filing  
9/1/2016Alvin ShihEVPSell8,750$16.24$142,100.00View SEC Filing  
6/1/2016Alvin ShihEVPSell8,750$17.75$155,312.50View SEC Filing  
3/4/2016Jeffrey A MecklerDirectorBuy5,000$15.31$76,550.00View SEC Filing  
3/3/2016Jeffrey A MecklerDirectorBuy10,000$14.45$144,500.00View SEC Filing  
3/1/2016Alvin ShihEVPSell8,750$14.35$125,562.50View SEC Filing  
12/9/2015Alvin ShihEVPSell8,750$20.83$182,262.50View SEC Filing  
11/2/2015Jensen Margaret E. ValeurGeneral CounselSell50,000$20.46$1,023,000.00View SEC Filing  
10/6/2015Alvin ShihEVPSell8,750$20.12$176,050.00View SEC Filing  
6/26/2015Alvin ShihEVPSell27,916$32.70$912,853.20View SEC Filing  
12/12/2014Horacio PlotkinInsiderSell2,100$10.07$21,147.00View SEC Filing  
11/25/2014Jeffrey A MecklerDirectorBuy15,000$8.60$129,000.00View SEC Filing  
11/21/2014Martin ShkreliInsiderSell1,172,000$8.84$10,360,480.00View SEC Filing  
11/21/2014Steve AselageCEOBuy10,000$8.46$84,600.00View SEC Filing  
11/21/2014Steven Gary RichardsonDirectorBuy6,100$8.38$51,118.00View SEC Filing  
11/19/2014Cornelius E GoldingDirectorBuy2,000$9.00$18,000.00View SEC Filing  
9/30/2014Martin ShkreliCEOBuy4,000$9.42$37,680.00View SEC Filing  
9/22/2014Martin ShkreliCEOBuy53,000$11.15$590,950.00View SEC Filing  
9/17/2014Martin ShkreliCEOBuy6,000$11.46$68,760.00View SEC Filing  
9/16/2014Martin ShkreliCEOBuy7,500$10.69$80,175.00View SEC Filing  
4/4/2014Martin ShkreliCEOBuy8,000$19.64$157,120.00View SEC Filing  
4/3/2014Martin ShkreliCEOBuy22,500$22.60$508,500.00View SEC Filing  
4/2/2014Martin ShkreliCEOBuy10,800$22.28$240,624.00View SEC Filing  
3/24/2014Martin ShkreliCEOBuy4,000$17.61$70,440.00View SEC Filing  
3/20/2014Martin ShkreliCEOBuy5,000$17.97$89,850.00View SEC Filing  
3/19/2014Martin ShkreliCEOBuy3,500$18.44$64,540.00View SEC Filing  
3/14/2014Martin ShkreliCEOBuy4,000$17.36$69,440.00View SEC Filing  
3/11/2014Martin ShkreliCEOBuy25,900$19.47$504,273.00View SEC Filing  
3/10/2014Martin ShkreliCEOBuy10,700$19.32$206,724.00View SEC Filing  
3/7/2014Martin ShkreliCEOBuy4,058$18.52$75,154.16View SEC Filing  
3/5/2014Martin ShkreliCEOBuy4,000$18.48$73,920.00View SEC Filing  
2/28/2014Martin ShkreliCEOBuy43,100$18.66$804,246.00View SEC Filing  
2/21/2014Martin ShkreliCEOBuy1,600$17.56$28,096.00View SEC Filing  
2/14/2014Martin ShkreliCEOBuy3,500$14.60$51,100.00View SEC Filing  
2/6/2014Martin ShkreliCEOBuy2,000$9.92$19,840.00View SEC Filing  
1/14/2014Martin ShkreliCEOBuy8,000$10.84$86,720.00View SEC Filing  
12/31/2013Martin ShkreliCEOBuy150,000$7.00$1,050,000.00View SEC Filing  
12/24/2013Cornelius E GoldingDirectorBuy3,000$7.50$22,500.00View SEC Filing  
11/5/2013Steven Gary RichardsonDirectorBuy2,900$6.90$20,010.00View SEC Filing  
9/12/2013Martin ShkreliCEOBuy11,112$4.50$50,004.00View SEC Filing  
8/22/2013Martin ShkreliCEOBuy3,900$6.06$23,634.00View SEC Filing  
8/15/2013Horacio PlotkinInsiderBuy2,200$4.50$9,900.00View SEC Filing  
8/15/2013Marc L PanoffCFOBuy1,100$4.50$4,950.00View SEC Filing  
3/4/2013Martin ShkreliCEOBuy1,000$4.43$4,430.00View SEC Filing  
2/20/2013Martin ShkreliCEOBuy1,120$4.16$4,659.20View SEC Filing  
2/14/2013Martin ShkreliCEOBuy120,000$3.00$360,000.00View SEC Filing  
2/12/2013Martin ShkreliCEOBuy1,400$3.57$4,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Retrophin (NASDAQ:RTRX)
DateHeadline
News IconRetrophin Inc RTRX Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:RTRX)
www.bioportfolio.com - February 19 at 9:06 AM
finance.yahoo.com logoRetrophin to Report Fourth Quarter and Full Year 2016 Financial Results (NASDAQ:RTRX)
finance.yahoo.com - February 16 at 7:19 PM
4-traders.com logoRetrophin : Appoints William Rote Senior Vice President, Research and Development (NASDAQ:RTRX)
www.4-traders.com - February 15 at 1:28 AM
globenewswire.com logoRetrophin Appoints William Rote Senior Vice President, Research and Development - GlobeNewswire (press release) (NASDAQ:RTRX)
globenewswire.com - February 14 at 6:05 AM
finance.yahoo.com logoRetrophin Appoints William Rote Senior Vice President, Research and Development (NASDAQ:RTRX)
finance.yahoo.com - February 14 at 6:05 AM
News IconTechnical Roundup On Two Stocks Retrophin, Inc. (RTRX), ImmunoGen, Inc. (IMGN) - Post Analyst (NASDAQ:RTRX)
postanalyst.com - February 12 at 8:15 AM
News IconForward Earnings Estimate of Retrophin, Inc.(RTRX) - Highland Mirror (NASDAQ:RTRX)
www.highlandmirror.com - February 12 at 12:44 AM
News IconGoldman Sachs Group Inc. is Buying Retrophin Inc. (NASDAQ:RTRX) Shares - Small Cap Exclusive (press release) (NASDAQ:RTRX)
smallcapexclusive.com - February 12 at 12:43 AM
News IconHealthcare Stocks Under Scanner -- Aerie Pharma, GW Pharma, Retrophin, and SciClone Pharma (NASDAQ:RTRX)
www.medindia.net - February 10 at 11:20 PM
nasdaq.com logoNoteworthy Thursday Option Activity: RTRX, PRU, DNB (NASDAQ:RTRX)
www.nasdaq.com - February 10 at 11:20 PM
News IconShares of Retrophin, Inc. (RTRX) Sees Large Outflow of Money - Highland Mirror (NASDAQ:RTRX)
www.highlandmirror.com - February 10 at 1:15 AM
msn.com logoShkreli involved in new company seeking $1 million in debt offering (NASDAQ:RTRX)
www.msn.com - February 8 at 11:41 PM
cnbc.com logoAccused fraudster Martin Shkreli involved in new company seeking $1 million in debt offering (NASDAQ:RTRX)
www.cnbc.com - February 8 at 11:41 PM
seekingalpha.com logoShkreli wins access to law firm records - Seeking Alpha (NASDAQ:RTRX)
seekingalpha.com - January 28 at 7:46 PM
seekingalpha.com logoShkreli, Greebel file severance motions - Seeking Alpha (NASDAQ:RTRX)
seekingalpha.com - January 28 at 7:46 PM
News IconRetrophin Inc RTRX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:RTRX)
www.bioportfolio.com - January 26 at 4:11 AM
News IconLombard Odier Asset Management Usa Corp Has Raised Its Holding in Retrophin INC (RTRX) by $16.38 Million (NASDAQ:RTRX)
randolphguide.com - January 24 at 10:32 PM
News IconWall Street Associates Cuts Position in Retrophin Inc (RTRX) by $2131781 - Highland Mirror (NASDAQ:RTRX)
www.highlandmirror.com - January 23 at 12:25 AM
News IconExclusive: Retrophin Inc Rises A lot Today, Is Now One of The Best ... - Fair View Times (NASDAQ:RTRX)
fairviewtimes.com - January 14 at 7:42 PM
seekingalpha.com logoRetrophin (RTRX) Presents At 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:RTRX)
seekingalpha.com - January 14 at 6:00 AM
seekingalpha.com logoBiotechs Sink After Trump Warns 'Drug Companies Get Away With Murder' (NASDAQ:RTRX)
seekingalpha.com - January 12 at 8:59 PM
seekingalpha.com logoMallinckrodt: With The FTC Kill A Depomed Bid? (NASDAQ:RTRX)
seekingalpha.com - January 12 at 3:07 AM
seekingalpha.com logoMallinckrodt: Will The FTC Kill A Depomed Bid? (NASDAQ:RTRX)
seekingalpha.com - January 10 at 10:17 PM
News IconFirst Week of RTRX February 17th Options Trading (NASDAQ:RTRX)
www.stockoptionschannel.com - January 9 at 9:12 PM
streetinsider.com logoRetrophin (RTRX) Sees Q4 Net Sales of $37M (NASDAQ:RTRX)
www.streetinsider.com - January 9 at 9:12 PM
us.rd.yahoo.com logoRetrophin Provides Corporate Update and 2017 Preview (NASDAQ:RTRX)
us.rd.yahoo.com - January 9 at 9:12 PM
biz.yahoo.com logoRETROPHIN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:RTRX)
us.rd.yahoo.com - January 9 at 9:12 PM
us.rd.yahoo.com logo8:05 am Retrophin sees Q4 revs of approximately $37 mln vs $35.95 mln Capital IQ Consensus Estimate, previews FY17 (NASDAQ:RTRX)
us.rd.yahoo.com - January 9 at 9:12 PM
streetinsider.com logoRetrophin (RTRX) Sees Q4 Net Sales of $37M - StreetInsider.com (NASDAQ:RTRX)
www.streetinsider.com - January 9 at 9:25 AM
reuters.com logo'Pharma bro' Shkreli suspended from Twitter for harassment (NASDAQ:RTRX)
www.reuters.com - January 8 at 7:27 PM
globenewswire.com logoRetrophin Appoints Elizabeth Reed General Counsel Nasdaq:RTRX - GlobeNewswire (press release) (NASDAQ:RTRX)
globenewswire.com - January 5 at 5:55 AM
publicnow.com logoRetrophin Appoints Elizabeth Reed General Counsel (NASDAQ:RTRX)
www.publicnow.com - January 5 at 5:55 AM
4-traders.com logoRetrophin : to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:RTRX)
www.4-traders.com - December 30 at 7:57 PM
globenewswire.com logoRetrophin to Present at the 35th Annual J.P. Morgan Healthcare ... - GlobeNewswire (press release) (NASDAQ:RTRX)
globenewswire.com - December 29 at 7:36 PM
finance.yahoo.com logoRetrophin to Present at the 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:RTRX)
finance.yahoo.com - December 29 at 7:36 PM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: Retrophin, Inc. (NASDAQ:RTRX) - Prospect Journal (NASDAQ:RTRX)
prospectjournal.com - December 27 at 9:23 AM
seekingalpha.com logoValeant Is Incorrigible (NASDAQ:RTRX)
seekingalpha.com - December 25 at 9:15 AM
News IconFollowing FCF Scores for Retrophin, Inc. (NASDAQ:RTRX) - Marion Business Daily (NASDAQ:RTRX)
marionbusinessdaily.com - December 18 at 8:01 PM
News IconVC Score In Focus for Retrophin, Inc. (NASDAQ:RTRX) - The Business Journal (NASDAQ:RTRX)
belmontbusinessjournal.com - December 18 at 1:16 AM
finance.yahoo.com logoJMP Conducts Retrophin Survey To Understand Story (NASDAQ:RTRX)
finance.yahoo.com - December 16 at 2:42 AM
News IconStock Spotlight: Zooming in on Shares of Retrophin, Inc. (NASDAQ:RTRX) - The Business Journal (NASDAQ:RTRX)
belmontbusinessjournal.com - December 14 at 1:02 AM
capitalcube.com logoRetrophin, Inc. breached its 50 day moving average in a Bearish Manner : RTRX-US : December 13, 2016 (NASDAQ:RTRX)
www.capitalcube.com - December 13 at 8:23 AM
News IconInvestor Watch on Shares of Retrophin, Inc. (NASDAQ:RTRX) - The Business Journal (NASDAQ:RTRX)
belmontbusinessjournal.com - December 9 at 1:05 AM
News IconInvestor Monitor: Narrowing in on Retrophin, Inc. (NASDAQ:RTRX) - The Business Journal (NASDAQ:RTRX)
belmontbusinessjournal.com - December 7 at 12:17 AM
News IconStock Update: Focusing on Shares of Retrophin, Inc. (NASDAQ:RTRX) - The Business Journal (NASDAQ:RTRX)
belmontbusinessjournal.com - December 3 at 6:41 PM
News IconFree Cash Flow Score in Focus for Retrophin, Inc. (NASDAQ:RTRX) - Marion Business Daily (NASDAQ:RTRX)
marionbusinessdaily.com - December 3 at 10:20 AM
capitalcube.com logoETFs with exposure to Retrophin, Inc. : December 2, 2016 (NASDAQ:RTRX)
www.capitalcube.com - December 2 at 11:47 AM
capitalcube.com logoRetrophin, Inc. breached its 50 day moving average in a Bearish Manner : RTRX-US : December 1, 2016 (NASDAQ:RTRX)
www.capitalcube.com - December 1 at 8:10 AM
News IconChecking the Metrics on Shares of Retrophin, Inc. (NASDAQ:RTRX) - The Business Journal (NASDAQ:RTRX)
belmontbusinessjournal.com - December 1 at 12:52 AM
globenewswire.com logoRetrophin to Present at the BMO Capital Markets Healthcare Conference - GlobeNewswire (press release) (NASDAQ:RTRX)
globenewswire.com - December 1 at 12:52 AM

Social

What is Retrophin's stock symbol?

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

Where is Retrophin's stock going? Where will Retrophin's stock price be in 2017?

3 equities research analysts have issued 1 year price targets for Retrophin's shares. Their predictions range from $28.00 to $46.00. On average, they expect Retrophin's share price to reach $35.33 in the next year.

When will Retrophin announce their earnings?

Retrophin is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

What are analysts saying about Retrophin stock?

Here are some recent quotes from research analysts about Retrophin stock:

  • According to Zacks Investment Research, "Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal®, Cholbam, and Thiola®, and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego. " (1/11/2017)

  • Leerink Swann analysts commented, "We believe the quarter signals turnaround on repricing in the core MA book of business." (5/11/2016)

Who owns Retrophin stock?

Retrophin's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Broadfin Capital LLC (8.66%), Perceptive Advisors LLC (7.12%), FMR LLC (4.16%), State Street Corp (3.18%), Franklin Resources Inc. (2.86%) and Kingdon Capital Management L.L.C. (1.10%). Company insiders that own Retrophin stock include Alvin Shih, Jeffrey A Meckler, Jensen Margaret E Valeur and Steve Aselage.

Who sold Retrophin stock? Who is selling Retrophin stock?

Retrophin's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Broadfin Capital LLC, Two Sigma Investments LP, Wall Street Associates, Oxford Asset Management, Franklin Resources Inc., Tudor Investment Corp Et Al and AQR Capital Management LLC. Company insiders that have sold Retrophin stock in the last year include Alvin Shih and Steve Aselage.

Who bought Retrophin stock? Who is buying Retrophin stock?

Retrophin's stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Bogle Investment Management L P DE, State Street Corp, Dimensional Fund Advisors LP, Paulson & CO. Inc., Renaissance Technologies LLC, Kingdon Capital Management L.L.C. and Russell Investments Group Ltd..

How do I buy Retrophin stock?

Shares of Retrophin can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Retrophin stock cost?

One share of Retrophin stock can currently be purchased for approximately $20.67.

Retrophin (NASDAQ:RTRX) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)

Earnings History Chart

Earnings by Quarter for Retrophin (NASDAQ:RTRX)

Dividend History Chart

Dividend Payments by Quarter for Retrophin (NASDAQ:RTRX)

Last Updated on 2/19/2017 by MarketBeat.com Staff